The November 10, 2009, article by Mandelli et al, entitled, “Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10” (J Clin Oncol 27:5397–5403, 2009), contained errors.
In the Abstract, under Results, the 5-year overall survival rates for daunorubicin, mitoxantrone, and idarubicin were given in the last sentence as 34%, 34%, and 31%, respectively, whereas they should have been 31%, 34%, and 34%, respectively. Also, because these data correspond to the global AML-10 population from diagnosis and not to the allografted patients as inferred, the last sentence should have been written as two separate sentences, as follows:
“The proportion of patients who underwent allogeneic SCT (22%) was equivalent in the three treatment groups, and the outcome was similar as well. The 5-year overall survival rates were 31%, 34%, and 34%, respectively.”
The authors apologize to the readers for the mistake.